Default company panoramic image

Savant HWP, Inc.

Savant HWP develops products that improve health, maintain wellness and prevent illness.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Carlos, CA, USA
  • Currency USD
  • Founded August 2009
  • Employees 9
  • Website

Company Summary

In September 2012, Savant received a $6.5 million grant from the National Institute on Drug Abuse (“NIDA”) to support the preclinical development of our lead compound, 18-MC for the treatment of cocaine abuse. Savant will seek additional funding from NIDA (up to $20 million) to support the clinical development of 18-MC. This funding is non-dilutive, does not restrict Savant’s freedom to operate and requires no repayment.


  • Default avatar
    Stephen L. Hurst
    President & CEO

    Mr. Hurst has more than twenty-five years experience in the biopharmaceutical industry and has contributed to the success of numerous complex and challenging healthcare projects. As the Chief Business Officer for The Immune Tolerance Institute (2007-2011), he helped establish a human immune monitoring institute for The Regents of the University of California that discovers and develops immune biomarkers. As a consultant to The World Bank and BI

  • Default avatar
    Scott M. Freeman
    Chairman & CMO

    Prior to joining Savant, Dr. Freeman was a drug development consultant for biotechnology and pharmaceutical companies. He served as Vice President of Clinical Development at Onyx Pharmaceutical (2001-2006) and was head of both clinical development and operations, which executed the clinical trials for renal cell, melanoma, liver, lung, and colorectal cancer. He successfully performed the Phase 1, 2, and 3 studies, which lead to NDA approval of

  • Default avatar
    Terence D. Boardman
    EVP, Global Manufacturing

    Prior to joining Savant, Dr. Boardman was a partner in the Enterprise Catalyst Group (ECG), a biopharmaceutical practice. Prior to joining ECG, he was Vice President of Operations for Sequential, Inc. (2002-2004) and was Vice President of Process Development and Manufacturing for Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.) (1995-2002). His experience spans both large pharmaceutical organizations and startup biotechnology c

  • Default avatar
    Mathew M. Lo
    SVP, Global R&D

    Dr. Lo held various positions at AstraZeneca within the Drug Discovery, Clinical Development and International Sales and Marketing Organizations, including, from 2010 to 2012, that of Senior Director and Product Development Team Leader at MedImmune LLC (an AstraZeneca subsidiary). Dr. Lo completed his PhD at Imperial College, University of London, in 1980. He was a postdoctoral fellow in the laboratory of Solomon H. Snyder at the Johns Hopkins U

  • Default avatar
    Jeanne M. Bonelle
    SVP, Global Quality

    Prior to joining Savant, Ms. Bonelle was an independent consultant within the health care industry working to establish development compliant quality and transitioning early phase quality systems to commercially compliant systems for drug products, biologic products, medical devices and OTC drugs. Ms. Bonelle has over thirty years of experience developing quality organizations within startup firms as well as transitioning to commercial operation


  • Default avatar
    Evan Ng, Dorsey & Whitney, LLP, Palo Alto
    Default avatar
    Armanino, LLP

Previous Investors

  • Default avatar